Interview: Paweł Mazur – East Area Director, Accord Healthcare, Poland
As east area director for the vast CEE market, Pawel Mazur explains how Accord Healthcare has gone from strength to strength in Poland, with the intention of becoming a top…
Address: ul. A & F Radziwill 9 , 05-850 Ozarow
Tel: (4822) 679-51-35
Web: http://www.vipharm.com.pl/
Vipharm S.A. is a Polish pharmaceutical company focusing for last 10 years on research, production and sale of specialist drugs.
Our drugs meet the requirements of Good Manufaktury Practice and Good Distribution Practice.
Safety and efficacy of our drugs has been confirmed by bioequivalence and bioavailability studies.
Vipharm S.A. still obtains excellent economical results, and is a successful competitor of the biggest manufacturers of medicines both on Polish and foreign markets. It has a leading position in respect of the value of sale and the amount of sold packages on Polish pharmaceutical market.
High quality of our drugs has been distinguished with Certificate of Innovation 2005 from PolishAcademy of Science and since 2008 year by year Vipharm S.A. has been distinguished with Certificate of Quality from PolishCenter of Research and Certification .
Scientific research over medicines investing after 10 years of activities in 2008 Vipharm started activity on international markets, on the territory of Czech, Slovakia, Hungary and Germany create trade companies Vipharm Slovakia s.r.o. Vipharm Hungary Kft. and Vipharm GmbH.
Vipharm S.A. specializing in the development, manufacturing and marketing of branded equivalents that help improve the quality of human life. As a manufacturer of medicines, it offers unique products, manufactured in modern, friendly area, according to GMP rules and the requirements of worldwide pharmacopoeias.
Our offer covers a wide range of therapeutic areas. However, we mainly concentrate on the therapy of Oncology and Central Nervous System diseases.
As east area director for the vast CEE market, Pawel Mazur explains how Accord Healthcare has gone from strength to strength in Poland, with the intention of becoming a top…
Krzysztof Popławski, general manager of Baxter Poland, discusses the Baxter Education Center, the largest educational program for a European affiliate, and its role in raising the awareness within the Polish…
Hubert Niemyjski, country manager of Coloplast Poland and the Baltics, highlights the large differences between the market landscape of the company’s three pillars; ostomy, wound and continence care. Additionally, he…
Olympus is internationally well-regarded as being a quality camera provider and continues to provide developed countries across the globe with high-tech medical devices from endoscopes to imagery solutions. Tomasz Mrzygłód,…
Paweł Migdalski, CEO at Siemens Healthineers Poland, discusses the innovations they are bringing to the market and how they are building on the success of the Siemens Healthineers Academy. Furthermore,…
Tomasz Dzitko, founder and CEO of Delfarma, Poland’s leading parallel importer, gives an overview of the sector in Poland and its impact on the healthcare ecosystem, as well as the…
Piotr Steczniewski, president of Profarm PS – a successful wholesale family business – since 2012, shares how the company has managed to thrive over the years through constant adaptation to…
Łukasz Korybalski, regional manager of Becton Dickinson (BD) Central Eastern Europe, discusses the rising significance of the region as the company continues to grow and the strategic importance of Poland,…
Marzena Kulis, managing director of Johnson & Johnson Medical Devices CEE, highlights the importance of the region and Poland within J&J Medical Devices, and the impact of increasing healthcare expenditures…
Despite the global R&D excitement around oncology, cardiovascular death still remains the world’s largest killer, and according to OECD data, accounts for roughly a third of all mortalities. This trend…
Cezary Kilczewski, president and founder of Medicofarma, a Polish CMO, discusses the company’s recent upgrades to double production capacity and the move into R&D operations as well as the dynamics…
Andrzej Schonert, CEO of Synoptis Industrial, discusses the intricacies of the Polish market and the requirement to move into niche areas, mainly in Rx, to concentrate their pharmaceutical offering to…
See our Cookie Privacy Policy Here
